MPN Advances Day 2017 | Potential of next-generation sequencing in the NHS for patients with MPNs

Angela Hamblin

Myeloproliferative Neoplasms (MPNs) carry a risk of complications, such as thrombosis; the degree of risk is influenced in part by genetic factors. In this interview, recorded at the Myeloproliferative Neoplasms Advances Day 2017 in London, UK, Angela Hamblin, MD, PhD, of Oxford Molecular Diagnostics Centre, Oxford UK, discusses how her team uses next-generation sequencing to identify known mutations in a patient sample, and the exciting applications that this may have in the future, including personalized treatment and minimal residual disease monitoring.

Share this video